S&P ASX All Technology

US Dollar vs AUD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

MRK Merck and Co Inc

130.34

0.22 (0.17%)

Last Updated: 02:24:02

Delayed by 15 minutes

Stronger technical forecast for Merck & Company Inc stock price after Monday trading.

The Merck & Company Inc stock price gained 2.09% on the last trading day (Monday, 4th Oct 2021), ris... View Full Article on StockInvest.us

Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2024 to May 2024

Click Here for more Merck Charts.

Merck (NYSE:MRK)
Historical Stock Chart
From May 2023 to May 2024

Click Here for more Merck Charts.

Merck and Co Inc News

Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults
Monday 29 April 2024 (1 day ago) • Business Wire

U.S. Stocks Climb Well Off Worst Levels But Close Mostly Lower
Friday 26 April 2024 (5 days ago) • IH Market News

Futures Pointing To Sharply Lower Open On Wall Street
Thursday 25 April 2024 (5 days ago) • IH Market News

Southwest Shares Tumble 9.6% Post $231 Million 1Q Loss, AstraZeneca Surges on 19% Annual Increase, and More on Earnings
Thursday 25 April 2024 (5 days ago) • IH Market News

Merck Announces First-Quarter 2024 Financial Results
Thursday 25 April 2024 (5 days ago) • Business Wire

Santé Canada approuve KEYTRUDA® comme traitement de première intention, en association avec une chimiothérapie à base de fluoropyrimidine et de platine, des adultes atteints d'un adénocarcinome gastrique ou de la jonction gastro-œsophagienne (JGO) H
Friday 19 April 2024 (2 weeks ago) • PR Newswire (Canada)

Delta Generates US$37 Million Profit in Q1, Google and Intel Unveil Cutting-Edge AI Chips, and More News
Wednesday 10 April 2024 (3 weeks ago) • IH Market News

Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
Thursday 4 April 2024 (4 weeks ago) • Business Wire

REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
Wednesday 3 April 2024 (4 weeks ago) • Business Wire

Merck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25
Monday 1 April 2024 (4 weeks ago) • Business Wire

European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in Adults
Thursday 28 March 2024 (1 month ago) • Business Wire

GameStop Shares Tumble 20% in Pre-Market Trading Amid Revenue Decline, Direct Digital Plummets 42%, and More News
Wednesday 27 March 2024 (1 month ago) • IH Market News

More Merck and Co Inc News Articles

Invesco QQQ Trust Series 1

Sterling vs AUD

AUD vs US Dollar

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions